Non-valvular Atrial Fibrillation

Cardiovascular
3
Pipeline Programs
5
Companies
9
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
EDOXABANApproved
edoxaban
Unknown Company
oral

Competitive Landscape

5 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
3 programs
1
1
EdoxabanPhase 41 trial
DU-176b 15mgPhase 31 trial
EdoxabanN/A1 trial
Active Trials
NCT04747496Completed5,000Est. Nov 2024
NCT01857622Completed93Est. Jan 2013
NCT03088072Unknown75Est. Dec 2019
Pfizer
PfizerNEW YORK, NY
3 programs
ApixabanN/A1 trial
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial FibrillationN/A1 trial
WarfarinN/A1 trial
Active Trials
NCT05321810Completed193,565Est. Apr 2022
NCT03002740Withdrawn0Est. Aug 2018
NCT05438888Completed77,814Est. Oct 2022
Bristol Myers Squibb
2 programs
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial FibrillationN/A
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial FibrillationN/A1 trial
Active Trials
NCT03087487Completed466,991Est. Mar 2023
Bayer
BayerLEVERKUSEN, Germany
2 programs
Non-VKA Oral AnticoagulantsN/A1 trial
RivaroxabanN/A
Active Trials
NCT04722679Completed103Est. Jan 2022
Abbott
AbbottABBOTT PARK, IL
1 program
Left Atrial AppendageN/A1 trial
Active Trials
NCT06189365Terminated50Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoEdoxaban
Daiichi SankyoDU-176b 15mg
AbbottLeft Atrial Appendage
PfizerWarfarin
PfizerApixaban
BayerNon-VKA Oral Anticoagulants
Daiichi SankyoEdoxaban
Bristol Myers SquibbClinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
PfizerBleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Clinical Trials (9)

Total enrollment: 743,691 patients across 9 trials

NCT03088072Daiichi SankyoEdoxaban

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Start: Mar 2017Est. completion: Dec 201975 patients
Phase 4Unknown
NCT01857622Daiichi SankyoDU-176b 15mg

Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Start: Nov 2011Est. completion: Jan 201393 patients
Phase 3Completed
NCT06189365AbbottLeft Atrial Appendage

Amplatzer Amulet China Post Market Study (PMS)

Start: Jan 2024Est. completion: Dec 202550 patients
N/ATerminated
NCT05438888PfizerWarfarin

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Start: Jul 2022Est. completion: Oct 202277,814 patients
N/ACompleted
NCT05321810PfizerApixaban

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Start: Apr 2022Est. completion: Apr 2022193,565 patients
N/ACompleted
NCT04722679BayerNon-VKA Oral Anticoagulants

A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.

Start: May 2021Est. completion: Jan 2022103 patients
N/ACompleted
NCT04747496Daiichi SankyoEdoxaban

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Start: Feb 2021Est. completion: Nov 20245,000 patients
N/ACompleted
NCT03087487Bristol Myers SquibbClinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

Start: Jun 2016Est. completion: Mar 2023466,991 patients
N/ACompleted
NCT03002740PfizerBleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Start: Jan 2016Est. completion: Aug 20180
N/AWithdrawn

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)